Evidence map›Paper›PMID 28165856›Full record

ArticleFly2017

secHsp70 as a tool to approach amyloid-β42 and other extracellular amyloids.

Lorena De Mena, Deepak Chhangani, Pedro Fernandez-Funez, Diego E Rincon-Limas

Open access · hybridAbstract read
In one paragraph

Article in Fly, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Heat Shock Proteins in Alzheimer's Disease: Role and Targeting.International journal of molecular sciences · 2018
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Lorena De Menaa Department of Neurology , McKnight Brain Institute University of Florida , Gainesville , FL , USA.ORCID 0000-0001-7096-0611
Deepak Chhangania Department of Neurology , McKnight Brain Institute University of Florida , Gainesville , FL , USA.ORCID 0000-0003-3971-7589
Pedro Fernandez-Funezb Department of Biomedical Sciences , University of Minnesota Medical School , Duluth , MN , USA.ORCID 0000-0002-0103-5593
Diego E Rincon-Limasa Department of Neurology , McKnight Brain Institute University of Florida , Gainesville , FL , USA.ORCID 0000-0003-3099-0642
University of Florida · USUniversity of Minnesota, Duluth · US

Funding

Engineering chaperones for extracellular amyloidsR21NS081356 · NINDS · UNIVERSITY OF FLORIDA · PI RINCON-LIMAS, DIEGO E · 2013 to 2014
$411k
Howard Hughes Medical InstituteNINDS NIH HHS R21 NS081356
6 · The paper itself

Abstract

Self-association of amyloidogenic proteins is the main pathological trigger in a wide variety of neurodegenerative disorders. These aggregates are deposited inside or outside the cell due to hereditary mutations, environmental exposures or even normal aging. Cumulative evidence indicates that the heat shock chaperone Hsp70 possesses robust neuroprotection against various intracellular amyloids in Drosophila and mouse models. However, its protective role against extracellular amyloids was largely unknown as its presence outside the cells is very limited. Our recent manuscript in PNAS revealed that an engineered form of secreted Hsp70 (secHsp70) is highly protective against toxicity induced by extracellular deposition of the amyloid-β42 (Aβ42) peptide. In this Extra View article, we extend our analysis to other members of the heat shock protein family. We created PhiC31-based transgenic lines for human Hsp27, Hsp40, Hsp60 and Hsp70 and compared their activities in parallel against extracellular Aβ42. Strikingly, only secreted Hsp70 exhibits robust protection against Aβ42-triggered toxicity in the extracellular milieu. These observations indicate that the ability of secHsp70 to suppress Aβ42 insults is quite unique and suggest that targeted secretion of Hsp70 may represent a new therapeutic approach against Aβ42 and other extracellular amyloids. The potential applications of this engineered chaperone are discussed.

Indexed as

Amyloid beta-PeptidesAmyloidosisAnimalsAnimals, Genetically ModifiedDisease Models, AnimalDrosophilaGene Expression RegulationHSP70 Heat-Shock ProteinsHumansMolecular ChaperonesPeptide FragmentsProtein BindingAmyloid beta-Peptidesamyloid beta-protein (1-42)HSP70 Heat-Shock ProteinsMolecular ChaperonesPeptide FragmentsAlzheimer diseaseAmyloid βataxin 3DrosophilaHsp27Hsp40Hsp60Hsp70neurodegenerationprotein misfolding

Identifiers

PMID28165856
PMCPMC5552267
OpenAlexW2586716694

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.